MDT

86.48

+0.17%↑

115.41

+0.39%↑

VEEV

173.76

-0.87%↓

HQY

84.36

+0.97%↑

PHR.US

8.25

-1.67%↓

MDT

86.48

+0.17%↑

115.41

+0.39%↑

VEEV

173.76

-0.87%↓

HQY

84.36

+0.97%↑

PHR.US

8.25

-1.67%↓

MDT

86.48

+0.17%↑

115.41

+0.39%↑

VEEV

173.76

-0.87%↓

HQY

84.36

+0.97%↑

PHR.US

8.25

-1.67%↓

MDT

86.48

+0.17%↑

115.41

+0.39%↑

VEEV

173.76

-0.87%↓

HQY

84.36

+0.97%↑

PHR.US

8.25

-1.67%↓

MDT

86.48

+0.17%↑

115.41

+0.39%↑

VEEV

173.76

-0.87%↓

HQY

84.36

+0.97%↑

PHR.US

8.25

-1.67%↓

Home・Elenco Azioni・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

23.76 2.9

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

23.14

Massimo

24.05

Metriche Chiave
By Trading Economics
Entrata	-7.3M -68M
Vendite	23M 68M
Margine di Profitto	-99.318
Dipendenti	298
EBITDA	42M -15M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+76.37% upside

Dividendi
By Dow Jones
Utili prossimi	4 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	253M 2B
Apertura precedente	20.86
Chiusura precedente	23.76

Notizie sul Sentiment di mercato

By Acuity

61%

39%

310 / 349 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

9.91 / 14.15 Supporto e resistenza

Syndax Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

1 apr 2026, 22:56 UTC

Principali Notizie su Eventi

Australian PM Set To Announce Interest-Free Loans For Businesses, Farmers

1 apr 2026, 20:50 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Extends Deadline on Tender Offer to Acquire Arcellx

1 apr 2026, 23:55 UTC

Discorsi di Mercato

Gold Rises on Hopes for Early End to U.S.-Iran Conflict -- Market Talk

1 apr 2026, 23:43 UTC

Discorsi di Mercato

Nikkei May Rise on Continued Hopes for U.S. Ending Iran War -- Market Talk

1 apr 2026, 23:23 UTC

Principali Notizie su Eventi

South Korea Consumer Inflation Accelerates on Mideast Energy Shock -- Update

1 apr 2026, 23:07 UTC

Utili

Shake Shack Leans on Loyalty Program and Tech to Drive Growth -- Barrons.com

1 apr 2026, 23:02 UTC

Principali Notizie su Eventi

South Korea Consumer Inflation Accelerates on Mideast Energy Shock

1 apr 2026, 23:00 UTC

Principali Notizie su Eventi

S Korea Mar CPI +0.3% on Month; +0.6% Forecast

1 apr 2026, 23:00 UTC

Principali Notizie su Eventi

S Korea Mar Core CPI +2.2% on Year, +0.1% on Month

1 apr 2026, 23:00 UTC

Principali Notizie su Eventi

S Korea Mar CPI +2.2% on Year; +2.4% Forecast

1 apr 2026, 22:39 UTC

Utili

Nike Can't Fix Its China Problem and That's Tanking Its Stock -- Update

1 apr 2026, 22:08 UTC

Discorsi di Mercato

KKR BDC Joins Others in Capping Withdrawals at 5% -- Market Talk

1 apr 2026, 22:00 UTC

Principali Notizie su Eventi

Mideast War Rekindles Asia Inflation Risk, Says DBS Chief Economist -- Interview

1 apr 2026, 22:00 UTC

Principali Notizie su Eventi

DBS Chief Economist: Rate Hikes Seem Likely in Japan, Singapore, Australia

1 apr 2026, 22:00 UTC

Principali Notizie su Eventi

DBS Chief Economist: BOK Could Also Take Proactive Approach Like RBA

1 apr 2026, 22:00 UTC

Principali Notizie su Eventi

DBS Chief Economist: India Vulnerable to War Imapct on Both Trade, Energy

1 apr 2026, 22:00 UTC

Principali Notizie su Eventi

DBS Chief Economist: China, Malaysia Looks Relatively Well-Insulated From War Fallout

1 apr 2026, 22:00 UTC

Principali Notizie su Eventi

DBS Chief Economist: Mideast Crisis Won't Hurt Asia Growth Much, Inflation a Bigger Issue

1 apr 2026, 22:00 UTC

Principali Notizie su Eventi

Inflationary Impact of Mideast Conflict Seems Inevitable, DBS Group Chief Economist Says

1 apr 2026, 21:56 UTC

Acquisizioni, Fusioni, Takeovers

BHP Completes $4.3 Billion Silver Streaming Agreement With Wheaton Precious Metals

1 apr 2026, 21:31 UTC

Principali Notizie su Eventi

End to Iran War Could Trigger Relief Rally in These 2 Assets -- Barrons.com

1 apr 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

1 apr 2026, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

1 apr 2026, 20:38 UTC

Utili

Why Nike Stock Is in 'Penalty Box' After Earnings Beat -- Barrons.com

1 apr 2026, 20:31 UTC

Acquisizioni, Fusioni, Takeovers

Arsenal Capital Partners Completes Sale of ATP Adhesive Systems to Henkel

1 apr 2026, 20:16 UTC

Acquisizioni, Fusioni, Takeovers

Gilead: Tender Offer Extended to Expire at 5 p.m. EDT on April 24 >GILD

1 apr 2026, 20:16 UTC

Acquisizioni, Fusioni, Takeovers

Gilead: Offer Remains at a Purchase Price of $115.00 per Shr >GILD

1 apr 2026, 20:13 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Extends Tender Offer To Acquire Arcellx >GILD

1 apr 2026, 20:07 UTC

Discorsi di Mercato

Mexican Manufacturing Indexes Pick Up in March -- Market Talk

1 apr 2026, 20:07 UTC

Acquisizioni, Fusioni, Takeovers

Why 2026 Is Biotech's Comeback Year -- Barrons.com

Confronto tra pari

Modifica del prezzo

Syndax Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

76.37% in crescita

Previsioni per 12 mesi

Media 41.2 USD 76.37%

Alto 57 USD

Basso 28 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Syndax Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

11 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 11 che hanno fornito valutazioni azionarie a Syndax Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

9.91 / 14.15Supporto e resistenza

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentiment

By Acuity

310 / 349 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.